[Market Focus] Tomocube Surges Over 6% After First Quarterly Profit

The share price of Tomocube, which has posted its first operating profit since its founding, is on the rise.

As of 9:45 a.m. on the 9th, Tomocube was trading at 58,600 won, up 3,400 won (6.16%) from the previous trading day.

On this day, Choi Seunghwan, a researcher at Shinhan Investment & Securities, said of Tomocube, "In the fourth quarter of last year, the company achieved sales of 5 billion won (up 449.1% year-on-year) and an operating profit of 400 million won, successfully returning to the black," adding, "With 44% of annual sales concentrated in the fourth quarter alone, the company proved its order-winning competitiveness with pharmaceutical companies and research institutions."

This year, earnings growth is expected to be driven by the global expansion of adoption of its flagship equipment, the "HT-X1," and the launch of the next-generation equipment, the "HT-X1 Max." The next-generation HT-X1 Max is currently undergoing work to standardize AI-based organoid (artificial organ) phenotype analysis in collaboration with major global pharmaceutical companies.

Researcher Choi stressed, "Medical artificial intelligence (AI) companies tend to see their share prices rapidly re-rated from the moment they prove their profitability," adding, "It is one of the companies that deserves the most attention this year."

This content was produced with the assistance of AI translation services.